Frontiers in Oncology (Sep 2021)
Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review
- Byeongsang Oh,
- Byeongsang Oh,
- Byeongsang Oh,
- Byeongsang Oh,
- Frances Boyle,
- Frances Boyle,
- Nick Pavlakis,
- Nick Pavlakis,
- Stephen Clarke,
- Stephen Clarke,
- Alex Guminski,
- Alex Guminski,
- Alex Guminski,
- Thomas Eade,
- Thomas Eade,
- Thomas Eade,
- Gillian Lamoury,
- Gillian Lamoury,
- Gillian Lamoury,
- Susan Carroll,
- Susan Carroll,
- Susan Carroll,
- Marita Morgia,
- Marita Morgia,
- Andrew Kneebone,
- Andrew Kneebone,
- Andrew Kneebone,
- George Hruby,
- George Hruby,
- George Hruby,
- Mark Stevens,
- Mark Stevens,
- Wen Liu,
- Brian Corless,
- Mark Molloy,
- Towia Libermann,
- Towia Libermann,
- David Rosenthal,
- Michael Back,
- Michael Back,
- Michael Back
Affiliations
- Byeongsang Oh
- Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia
- Byeongsang Oh
- Cancer Care Service, Mater Hospital, North Sydney, NSW, Australia
- Byeongsang Oh
- Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
- Byeongsang Oh
- University of Kansas Medical Center, Kansas City, KS, United States
- Frances Boyle
- Cancer Care Service, Mater Hospital, North Sydney, NSW, Australia
- Frances Boyle
- Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
- Nick Pavlakis
- Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia
- Nick Pavlakis
- Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
- Stephen Clarke
- Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia
- Stephen Clarke
- Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
- Alex Guminski
- Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia
- Alex Guminski
- Cancer Care Service, Mater Hospital, North Sydney, NSW, Australia
- Alex Guminski
- Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
- Thomas Eade
- Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia
- Thomas Eade
- Cancer Care Service, Mater Hospital, North Sydney, NSW, Australia
- Thomas Eade
- Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
- Gillian Lamoury
- Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia
- Gillian Lamoury
- Cancer Care Service, Mater Hospital, North Sydney, NSW, Australia
- Gillian Lamoury
- Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
- Susan Carroll
- Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia
- Susan Carroll
- Cancer Care Service, Mater Hospital, North Sydney, NSW, Australia
- Susan Carroll
- Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
- Marita Morgia
- Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia
- Marita Morgia
- Cancer Care Service, Mater Hospital, North Sydney, NSW, Australia
- Andrew Kneebone
- Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia
- Andrew Kneebone
- Cancer Care Service, Mater Hospital, North Sydney, NSW, Australia
- Andrew Kneebone
- Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
- George Hruby
- Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia
- George Hruby
- Cancer Care Service, Mater Hospital, North Sydney, NSW, Australia
- George Hruby
- Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
- Mark Stevens
- Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia
- Mark Stevens
- Cancer Care Service, Mater Hospital, North Sydney, NSW, Australia
- Wen Liu
- University of Kansas Medical Center, Kansas City, KS, United States
- Brian Corless
- Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia
- Mark Molloy
- Bowel Cancer and Biomarker Laboratory, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
- Towia Libermann
- Beth Israel Deaconess Medical Center (BIDMC) Genomics, Proteomics, Bioinformatics and Systems Biology Center, Beth Israel Deaconess Medical Center, Boston, MA, United States
- Towia Libermann
- Harvard Medical School, Boston, MA, United States
- David Rosenthal
- Harvard Medical School, Boston, MA, United States
- Michael Back
- Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia
- Michael Back
- Cancer Care Service, Mater Hospital, North Sydney, NSW, Australia
- Michael Back
- Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
- DOI
- https://doi.org/10.3389/fonc.2021.706331
- Journal volume & issue
-
Vol. 11
Abstract
Increasing evidence suggests that the gut microbiome is associated with both cancer chemotherapy (CTX) outcomes and adverse events (AEs). This review examines the relationship between the gut microbiome and CTX as well as the impact of CTX on the gut microbiome. A literature search was conducted in electronic databases Medline, PubMed and ScienceDirect, with searches for “cancer” and “chemotherapy” and “microbiome/microbiota”. The relevant literature was selected for use in this article. Seventeen studies were selected on participants with colorectal cancer (CRC; n=5), Acute Myeloid Leukemia (AML; n=3), Non-Hodgkin’s lymphoma (n=2), breast cancer (BCa; n=1), lung cancer (n=1), ovarian cancer (n=1), liver cancer (n=1), and various other types of cancers (n=3). Seven studies assessed the relationship between the gut microbiome and CTX with faecal samples collected prior to (n=3) and following CTX (n=4) showing that the gut microbiome is associated with both CTX efficacy and toxicity. Ten other prospective studies assessed the impact of CTX during treatment and found that CTX modulates the gut microbiome of people with cancer and that dysbiosis induced by the CTX is related to AEs. CTX adversely impacts the gut microbiome, inducing dysbiosis and is associated with CTX outcomes and AEs. Current evidence provides insights into the gut microbiome for clinicians, cancer survivors and the general public. More research is required to better understand and modify the impact of CTX on the gut microbiome.
Keywords
